Chemotherapy News and Research

Latest Chemotherapy News and Research

TNFerade's suppression of cancer metastases: Mechanisms revealed

GenVec, Inc. announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system.

4 Mar 2010

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Cell Therapeutics, Inc. announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.

4 Mar 2010

Recurrence of breast cancer in older women: Delaying post-surgical radiation treatment increases risk

Older women who have had breast cancer surgery have a greater risk of the cancer returning if they delay their post-surgical radiation treatment, report Dana-Farber Cancer Institute scientists.

4 Mar 2010

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Endocyte, Inc., a biotech company developing guided therapeutics and diagnostics for personalized medicine, has announced that an independent data safety monitoring board (DSMB) recommended that enrollment into the PRECEDENT study continue.

4 Mar 2010

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy.

4 Mar 2010

$Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer$

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.

3 Mar 2010

Seattle Genetics generates $110M through ADC technology license agreements

Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech, Inc., a wholly owned member of the Roche Group.

3 Mar 2010

Aggressive treatment of anemia with ESAs may lower risk of death for dialysis patients: Study

Aggressive treatment of anemia with intravenous iron and drugs known as erythropoiesis-stimulating agents (ESAs) may lower the risk of death for dialysis patients with severe anemia - but also may increase the risk of death among patients with milder anemia, a new study led by a University of North Carolina at Chapel Hill epidemiologist suggests.

3 Mar 2010

PINC trial to test anti-malarial drug in women with DCIS

Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive? That's what researchers at George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM) and Inova Breast Care Institute (IBCI) are trying to prove.

3 Mar 2010

Starting radiotherapy as soon as possible could minimise breast cancer recurrence

The longer women wait for radiotherapy after breast cancer surgery, the more chance there is of local recurrence, concludes a study published on bmj.com today.

3 Mar 2010

Solasia Pharma K.K. signs License and Supply Agreement with Kyowa Hakko Kirin to market SP-01

Solasia Pharma K.K. (http://www.solasia.co.jp), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the signing of a License and Supply Agreement with Kyowa Hakko Kirin that provides Kyowa Hakko Kirin with an exclusive right to market and sell SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Taiwan, Hong Kong, Singapore and Malaysia.

3 Mar 2010

IntelliDose introduces new, integrated clinical software for medical oncology practices

IntelliDose®, a leading clinical software to manage medical oncology practices, today introduces IntelliScribe™ – a new, fully integrated module in the IntelliDose workflow – to electronically generate prescriptions at any point in the chemotherapy order writing process.

3 Mar 2010

NPS Pharmaceuticals sells royalty rights from sales of REGPARA to DRI Capital's fund

NPS Pharmaceuticals, Inc. today announced the sale of its royalty rights from sales of REGPARA® (cinacalcet HCl) to a fund managed by DRI Capital, Inc., (Fund) for $38.4 million. Royalties in excess of cumulative royalties of $96 million or 2.5 times the upfront purchase price have been retained by NPS.

3 Mar 2010

Findings could lead to new cancer-fighting drugs

A new study is providing insight into how estrogen fuels many breast cancers, and researchers say the findings could lead to new cancer-fighting drugs.

3 Mar 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

Combination of two targeted therapies effective against subset of gastric cancers: Study

A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's Jonsson Comprehensive Cancer Center has found.

3 Mar 2010

Cleveland HeartLab completes $3.0M fundraising round

Cleveland HeartLab LLC (CHL) today announced that it has completed a $3.0-million fundraising round. The company’s new shareholders include local business leaders, and Glengary LLC, Second Generation Ltd. and Zapis Capital Group LLC.

2 Mar 2010

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.

2 Mar 2010

RMEI and PIM sponsor education webcast on therapeutic considerations for CRPC

Castrate-refractory prostate cancer (CRPC), which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for treatment of CRPC are lacking and healthcare professionals must consider several factors, including serum markers, patient age and pre-existing comorbidities when choosing between second-line hormonal therapy and chemotherapy for treatment of CRPC.

2 Mar 2010

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

2 Mar 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

TNFerade's suppression of cancer metastases: Mechanisms revealed

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Recurrence of breast cancer in older women: Delaying post-surgical radiation treatment increases risk

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Seattle Genetics generates $110M through ADC technology license agreements

Aggressive treatment of anemia with ESAs may lower risk of death for dialysis patients: Study

PINC trial to test anti-malarial drug in women with DCIS

Starting radiotherapy as soon as possible could minimise breast cancer recurrence

Solasia Pharma K.K. signs License and Supply Agreement with Kyowa Hakko Kirin to market SP-01

IntelliDose introduces new, integrated clinical software for medical oncology practices

NPS Pharmaceuticals sells royalty rights from sales of REGPARA to DRI Capital's fund

Findings could lead to new cancer-fighting drugs

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Combination of two targeted therapies effective against subset of gastric cancers: Study

Cleveland HeartLab completes $3.0M fundraising round

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

RMEI and PIM sponsor education webcast on therapeutic considerations for CRPC

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in